PFIZER, INC.

(PFE)
  Report
Delayed Nyse  -  04:04 2022-08-16 pm EDT
49.86 USD   +0.22%
04:29pPlaintiff in first Zantac lawsuit set for trial drops case
RE
04:22pAmbrx Biopharma Names Kate Hermans Interim CEO
MT
03:54pPFIZER : Statement from Pfizer Chairman and CEO Albert Bourla on Testing Positive for COVID-19
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Arbitrator Rules Employer's Two-Dose COVID Vaccine Requirement Not Reasonable (Anymore…)

07/01/2022 | 02:09pm EDT

In what appears to be a significant departure from recent arbitral decisions, an employer's COVID-19 vaccination policy has been deemed unreasonable in light of new scientific data. In FCA Canada Inc. v Unifor, Locals 195, 444, 1285, the Employer implemented its policy on October 14, 2021. The policy required, in part, that employees, contractors, suppliers, and visitors were required to be fully vaccinated with two doses of a two-dose vaccine in order to attend the workplace. If an employee did not abide by this requirement of the policy, they would be placed on unpaid leave of absence, and possibly terminated for non-compliance. The Union grieved that the policy was once reasonable, but now was not. The parties presented their arguments on May 25, 2022 and Arbitrator Marilyn Nairn eventually ruled that the two-dose vaccine requirement was unreasonable.

At hearing, the Union argued that recent scientific studies had shown that two-dose vaccines were no longer effective against transmitting COVID (specifically with regard to the vaccines' effectiveness against the Omicron variant). Hence, the Union argued that the vaccination policy be deemed unreasonable, and employees who are on unpaid leave be fully compensated.

The Employer argued that the evolution in the scientific evidence was not as clear and consistent as the Union suggested, and that vaccines remained effective in preventing serious illnesses. Moreover, Public Health guidelines still encouraged vaccinations as a means to prevent unvaccinated individuals from becoming infected and transmitting COVID to those who are vaccinated.

The Arbitrator noted from the outset of her decision that "The fundamental factor in dispute in this case is the reasonableness of the Policy in the circumstances of the Employer's workplaces in the context of changing nature of the COVID-19 pandemic." In order to assess that context, the Arbitrator considered, among other things, the following findings from various global scientific studies:

<ul
  • A pre-print study from the U.K. Health Security Agency reviewed vaccine effectiveness against the Omicron variant. It concluded that primary series immunization (2 doses) with either Pfizer or AstraZeneca provided limited or no protection against infection and mild disease. Boosting with the Pfizer vaccine was found to offer an increase in protection, but at the time that this study was conducted, the duration of that increased protection was not known.
  • Another study by the U.K. Health Security Agency, published April 28, 2022, concluded that, while vaccine effectiveness against Omicron from two doses of an mRNA vaccine dropped from 65-70% to about 15% by week 25, booster doses of an mRNA vaccine provided some renewed protection against symptomatic Omicron infections. Protection against hospitalization and death related to COVID-19 remained strong after a second dose but was more robust after a booster dose.
  • A Danish pre-print study published in December 2021 found that the comparative levels of transmission between an infected unvaccinated and infected two-dose vaccinated person was statistically insignificant.
  • Decision/Rationale:

    The Arbitrator took care to review previous decisions upholding the reasonableness of workplace COVID-19 vaccine policies, of which there are many that you can review in CCPartners' Complete Rundown of COVID-19 Vaccine Policy Decision. In particular, she rejected the idea that employees had a blanket entitlement to remain unvaccinated without consequence, stating:

    I observe that there is no "right" to remain unvaccinated and remain in active employment. The right is one of personal autonomy and bodily integrity, in this circumstance, having the choice to remain unvaccinated. Exercising that choice may give rise to other impacts. For every right there is a corresponding responsibility - the Employer has the right to make workplace rules but has the corresponding responsibility to ensure that those rules are reasonable. An employee has the right to remain unvaccinated but has a corresponding responsibility not to place co-workers at increased risk as a result. Notably, the tension between these two interests can be acute, because a COVID-19 vaccine mandate was not an original condition of employment but has been newly introduced into the workplace, affecting existing employees who are now faced with what, for some, is a significantly difficult choice between remaining unvaccinated or continuing in active employment.

    Indeed, it was a factual finding based on the available studies that the Arbitrator found compelling. She decided that "Emerging evidence does indicate that a two-dose vaccine regimen provides significantly less protection against infection from Omicron and its sub-variants than with prior variants."

    Accordingly, and in the particular and discrete circumstances of this case, the Arbitrator declared that the Employer's policy was indeed unreasonable:

    ...I hereby find that a COVID-19 vaccine mandate defined as requiring two doses (of a two-dose vaccine) is no longer reasonable based on the evidence supporting the waning efficacy of that vaccination status and the failure to establish that there is any notable difference in the degree of risk of transmission of the virus as between the vaccinated (as defined in the Policy) and the unvaccinated. Rather, the evidence supports a conclusion that there is negligible difference in the risk of transmission in respect of Omicron as between a two-dose vaccine regimen and remaining unvaccinated. There is, under the definition in the Policy, no longer a basis for removing unvaccinated employees from the workplace...

    Arbitrator Nairn declared the policy to be of no force or effect as of June 25, 2022. However, she left the door open for the Employer to revise the policy rather than vacate it altogether.

    Takeaways for Employers

    This case illustrates that while there may be still be uncertainty about how vaccination policies will be interpreted in the future, recent and developing scientific evidence are a crucial factor in determining whether a policy will be considered reasonable by labour arbitrators. Arbitrator Nairn could not have been more clear that her decision was based on the particular circumstances of these workplaces over the relevant period, in relation to the Policy as written and the available science. She noted that any or all of those circumstances may change, which accordingly could change the outcome of a similar grievance.

    Employers who are reconsidering their COVID-19 vaccination policies should take steps to understand the factual context in which they operator, including public health guidance and scientific consensus.

    The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

    Khushi Dave
    CCPartners
    Suite 500, 24 Queen Street East
    Brampton
    Ontario
    L6V 1A3
    CANADA
    Tel: 9058749343
    Fax: 9058741384
    E-mail: ajeffers@ccpartners.ca
    URL: www.ccpartners.ca

    © Mondaq Ltd, 2022 - Tel. +44 (0)20 8544 8300 - http://www.mondaq.com, source Business Briefing

    All news about PFIZER, INC.
    04:29pPlaintiff in first Zantac lawsuit set for trial drops case
    RE
    04:22pAmbrx Biopharma Names Kate Hermans Interim CEO
    MT
    03:54pPFIZER : Statement from Pfizer Chairman and CEO Albert Bourla on Testing Positive for COVI..
    PU
    06:43aPfizer Inc. - Statement from Pfizer Chairman and CEO Albert Bourla on Testing Positive ..
    AQ
    04:44aDigital innovations and congress coverage led to an increase in all hub users
    AQ
    08/15Pfizer CEO tests positive for COVID-19, has mild symptoms
    AQ
    08/15Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal..
    AQ
    08/12Creighton students' COVID vaccine mandate appeal dismissed
    AQ
    08/12Drugmakers' shares up after Zantac lawsuit slump
    RE
    08/12Biotech stocks pin bounce back hopes on M&A boost
    RE
    More news
    Analyst Recommendations on PFIZER, INC.
    More recommendations
    Financials (USD)
    Sales 2022 102 B - -
    Net income 2022 32 675 M - -
    Net cash 2022 11 522 M - -
    P/E ratio 2022 8,85x
    Yield 2022 3,25%
    Capitalization 280 B 280 B -
    EV / Sales 2022 2,64x
    EV / Sales 2023 3,35x
    Nbr of Employees 79 000
    Free-Float 59,0%
    Chart PFIZER, INC.
    Duration : Period :
    Pfizer, Inc. Technical Analysis Chart | MarketScreener
    Full-screen chart
    Technical analysis trends PFIZER, INC.
    Short TermMid-TermLong Term
    TrendsBearishNeutralNeutral
    Income Statement Evolution
    Consensus
    Sell
    Buy
    Mean consensus OUTPERFORM
    Number of Analysts 22
    Last Close Price 49,86 $
    Average target price 56,53 $
    Spread / Average Target 13,4%
    EPS Revisions
    Managers and Directors
    Albert Bourla Chairman, Chief Executive & Operating Officer
    David M. Denton Chief Financial Officer & Executive Vice President
    Mikael Dolsten Executive VP, President-Research & Development
    Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
    Aida Habtezion Chief Medical Officer
    Sector and Competitors
    1st jan.Capi. (M$)
    PFIZER, INC.-15.56%279 215
    JOHNSON & JOHNSON-2.91%436 680
    ELI LILLY AND COMPANY13.66%298 298
    ROCHE HOLDING AG-16.14%277 502
    ABBVIE INC.5.09%251 582
    NOVO NORDISK A/S5.65%241 077